🟢 Biovie is trading 11.38% up in pre-market after positive Phase 2 SUNRISE-PD results

Biovie is trading at $2.07, up 11.38% in pre-market after positive Phase 2 SUNRISE-PD results for bezisterim in early Parkinson’s disease.

• The trial met its primary endpoint, showing statistically significant clinical and biomarker improvements versus placebo, with a placebo-like safety profile.
• A newly reported Schedule 13G beneficial-ownership filing supported investor interest; no distinct August 21 announcement was identified.
• The move follows two consecutive strong sessions, while U.S. futures are higher; the clinical update remains the primary identifiable catalyst.